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S U M M A R Y
Background: Rotavirus vaccination was introduced in Panama in March 2006. This study was carried out
in order to describe the trends in gastroenteritis-related (GER) hospitalizations and mortality in children
<5 years of age during the pre- and post-vaccination periods.
Methods: Data from the Expanded Program on Immunization (Ministry of Health) were used to calculate
vaccine coverage. GER mortality and hospitalizations were obtained through database review of the
Contralorı´a General de la Repu´blica and hospital discharge databases of ﬁve sentinel hospitals, for the
period 2000–2008. Mean rates of GER mortality and mean numbers of hospitalizations during the
baseline pre-vaccination period (2000-2005) were compared to those of 2007 and 2008.
Results: National coverage for the second rotavirus vaccine dose increased from 30% in 2006 to 62% in
2007 and 71% in 2008, varying from 62% in the West region to 77% in the Panama region. Overall, at 2-
years post-vaccine introduction, the GER mortality rate in Panama had decreased by 50% (95%
conﬁdence interval (CI) 46–54). During 2000–2005, the GER mortality rate in children (<1 year) was 73/
100 000, decreasing by 45% (95% CI 40–51) in 2008. In children aged 1–4 years, the GER mortality rate
was 20.3/100 000 (2000–2005), decreasing by 54% (95% CI 48–60) in 2008. The Panama region registered
the highest mortality rate reduction (69%; 95% CI 58–81) for 2008. During 2008, GER hospitalizations
among children <5 years of age decreased by 30% (95% CI 21–37) from the mean number of
hospitalizations during 2000–2005.
Conclusions: A substantial reduction in GER mortality and hospitalizations was observed following the
introduction of rotavirus vaccine in Panama.
 2011 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Globally, rotavirus (RV) is the most common cause of acute
diarrhea requiring hospitalization among infants and young
children. Annually, rotavirus has caused over 611 000 deaths
(range 454 000–705 000), approximately 2.4 million hospitaliza-
tions, and over 25 million clinic visits worldwide among children
<5 years of age;1–3 more than 85% of these deaths occur in low-
income countries of Asia and Africa.4 The case fatality rate is often
higher among children in low-income countries,5 though its
incidence is similar in developed and developing countries.5,6 As
per the World Health Organization (WHO) rotavirus surveillance
network, approximately 40% (range 10–59%) of diarrhea hospita-* Corresponding author. Tel.: +507 5274811; fax: +507 5274889.
E-mail address: vicentebayard@hotmail.com (V. Bayard).
1201-9712/$36.00 – see front matter  2011 International Society for Infectious Disea
doi:10.1016/j.ijid.2011.09.003lizations among children <5 years of age worldwide, and 34%
(range 10–51%) in the region of the Americas, were attributed to
rotavirus infection prior to vaccine introduction.7 In Latin America,
over 15 000 deaths, 75 000 hospitalizations, and 10 million cases of
rotavirus diarrhea were reported annually.4 In Panama, prior to
vaccine introduction, an estimated 15% of infants <6 months of age
and 85% of infants <1 year old had had at least one episode of
rotavirus infection.8
In order to reduce the global disease burden due to rotavirus
gastroenteritis, effective and safe vaccines have been devel-
oped2,3,9,10 and are now recommended by the WHO for inclusion
in national immunization programs.9 Two oral rotavirus vaccines
are available in more than 100 countries worldwide: a two-dose
human-attenuated rotavirus vaccine RIX4414 (Rotarix
TM
; GlaxoS-
mithKline Biologicals, Rixensart, Belgium) and a three-dose live
pentavalent bovine–human reassortant vaccine (Rotateq
TM
; Merck,
Whitehouse Station, NJ, USA). Both vaccines have demonstrated anses. Published by Elsevier Ltd. All rights reserved.
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against all-cause acute gastroenteritis (42–59%) in clinical
trials.11,12 Based on these encouraging results, some of the
countries of Latin America, including Brazil, Venezuela, El Salvador,
and Mexico, have introduced rotavirus vaccines into their national
programs (up until 2007).13 In March 2006, Panama introduced the
human-attenuated rotavirus vaccine into its Expanded Program on
Immunization (EPI) for the entire Panamanian birth cohort (70 000
children per year) using a two-dose scheme for children under 6
months.14
The WHO recommends that vaccine impact be assessed by
monitoring trends in hospitalizations and mortality from all-cause
acute gastroenteritis using secondary data sources.15 Following the
introduction of rotavirus vaccines into immunization programs,
global rotavirus surveillance networks were established to
monitor the performance of the vaccines.13,16 The present study
was undertaken to evaluate gastroenteritis-related (GER) hospi-
talizations and mortality trends in children <5 years of age before
and after the introduction of rotavirus vaccination in Panama.
2. Methods
Data on the number of rotavirus vaccine doses administered as
ﬁrst and second doses by region were obtained from the EPI of the
Panamanian Ministry of Health. Vaccine coverage was calculated
for the age group <1 year using the population estimated by the
census as the denominator and stratiﬁed by region, as follows: (1)
West region (Bocas del Toro, Chiriquı´, and Comarca Ngo¨be Bugle´),
(2) Central region (Cocle´, Herrera, Los Santos, and Veraguas), (3)
Panama region (East Panama, West Panama, Metropolitan Panama,
and San Miguelito), and (4) Northeast region (Colo´n, Darie´n, and
Comarca Kuna Yala).
National mortality data for GER outcomes in children <5 years
of age during 2000–2008 were obtained from the Contralorı´a
General de la Repu´blica (CGR) databases. The Vital Statistics
Department of CGR from Panama is responsible for data on main/
primary cause of death obtained from death certiﬁcates, and has an
estimated coverage of >85% of all deaths reported in Panama.
Mortality data are recorded at the municipality level, reported,
reviewed, and entered into the province database, and transmitted
electronically to the national level. Data from the CGR are the
recognized ofﬁcial national mortality data.
There are 13 main hospitals nationwide providing pediatric
medical care (two tertiary care and 11 secondary care hospitals).
We reviewed the databases of the main ﬁve hospitals representing
different settings in Panama (three urban hospitals: Hospital del
Nin˜o, Hospital de Especialidades Pediatricas, Hospital San Miguel
Arcangel; one suburban: Hospital Nicolas Solano; and one rural:
Hospital de Changuinola), which are considered as reference
hospitals for pediatric care across the country.
Both GER mortality and hospitalization data were collected
using the International Classiﬁcation of Diseases, 10th revision
(ICD-10), including diarrhea and gastroenteritis of presumed
infectious origin (A09X). Annual GER mortality rates were
calculated using the population estimates from population data
in the census as the denominator. The mean rate of GER mortality
and number of hospitalizations during 2000–2005 was used as the
baseline against which to compare the post-vaccination years
(2007 and 2008). As rotavirus vaccine was introduced in Panama in
early 2006, this year was considered a transitional year and
excluded from the analysis. The absolute and relative reduction in
deaths and mortality rates were computed with 95% conﬁdence
intervals (CI) using the exact Poisson conﬁdence limit.17 Analysis
was stratiﬁed according to age groups <1 year and 1–4 years and
by region. All statistical analyses were performed using SAS v. 9.1,
Epi Info v. 3.4.3, and Microsoft Excel.3. Results
3.1. Rotavirus vaccine coverage
A total of 284 328 rotavirus vaccine doses, 60% as ﬁrst doses and
40% as second doses, were administered between March 2006 and
December 2008 to children aged <1 year in Panama. Vaccine
coverage of the ﬁrst dose in children <1 year of age was 62% in
2006, 89% in 2007, and 91% in 2008, while second dose coverage
was 30%, 62%, and 71%, respectively. Vaccine coverage varied
across regions. The Panama region had the highest two-dose
coverage in the country, with 70% in 2007 and 77% in 2008, in
comparison to the other regions, as shown in Figure 1. However, all
regions showed an increase in vaccine coverage over time for both
doses.
3.2. GER mortality
From 2000 to 2008, 883 GER deaths were reported among
children <5 years of age in Panama; 424 (48%) in children <1 year
of age and 459 (52%) in children aged 1–4 years. The mean number
of GER deaths in children <5 years of age during the pre-
vaccination period of 2000–2005 was 103 (95% CI 92–112). Most of
these cases occurred in the West region (60%). All regions reported
a reduction in the number of GER deaths in children <5 years of age
during 2008, with the highest reduction in the Panama region
(66%; 95% CI 55–72) and the lowest reduction in the Northern
region (33%; 95% CI 12–52) (Figure 2). Overall, the number of
deaths in children <5 years of age was reduced by 47% (95% CI 41–
52). The absolute number of GER deaths in children aged <1 year
and 1–4 years decreased from a mean of 49 and 54, respectively,
during the pre-vaccination period, to 28 (43%; 95% CI 38–47) and
26 (51%; 95% CI 43–58), respectively, during 2008.
Trends in the GER mortality rate are presented in Figure 3. The
GER mortality rate in children under 5 years of age during 2000–
2005 was 31.1 per 100 000 children and decreased by 50% (95% CI
46–54) in 2008, with a rate of 15.5 per 100 000 children (Table 1).
The highest mortality rate prior to vaccine introduction was
observed in the West region, with a mean of 79.9 per 100 000
children, decreasing by 48% (95% CI 43–52) in 2008. The Panama
region registered the highest reduction in mortality rate of 69%
(95% CI 58–81) for 2008. In children <1 year of age, the GER
mortality rate during 2000–2005 was 73 per 100 000 children,
decreasing by 45% (95% CI 40–51) during 2008. In children 1–4
years of age, the GER mortality rate during 2000–2005 was 20.3 per
100 000 children, decreasing by 54% (95% CI 48–60) in 2008.
3.3. GER hospitalizations
During 2000–2008, a total of 26 700 GER hospitalizations were
observed in children <5 years of age at the ﬁve pediatric hospitals
included in this study. During the pre-vaccination period (2000–
2005), 18 021 GER hospitalizations were observed in children <5
year of age, with a mean of 3004 hospitalizations per year (95% CI
2671–3336) during 2000–2005, decreasing by 4% (95% CI 8–13)
and 30% (95% CI 21–37) in 2007 and 2008, respectively. Over 67% of
GER hospitalizations in children <5 years of age were at the
Hospital del Nin˜o during the pre-vaccination period, the main
reference pediatric hospital in Panama, in which reductions of 36%
(95% CI 10–50) in 2007 and 43% (95% CI 19–55) in 2008 were
observed.
Among children <1 year of age, 6372 GER hospitalizations were
observed during 2000–2005, with a mean of 1062 (95% CI 913–
1210) hospitalizations per year, decreasing by 7% (95% CI 1–18) in
2007 and 28% (95% CI 4–17) in 2008. In children 1–4 years of age,
11 649 GER hospitalizations occurred during 2000–2005, with a
Figure 1. Vaccine coverage (%) in children <1 year of age by vaccine dose and region, Panama, 2006–2008. (Source: Vaccination information from the Expanded Program on
Immunization (EPI) of the Ministry of Health in Panama; population data provided by the Directorate of Statistics based on the population census of the CGR).
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(95% CI 11–13) in 2007 and 31% (95% CI 20–38) in 2008 (Figure 4).
4. Discussion
The present study used secondary data sources to monitor
trends in GER morbidity and mortality in children <5 years of age,
before and after the introduction of the human-attenuated
rotavirus vaccine into the EPI in Panama in March 2006. In
2008, just 2 years after national rotavirus vaccine introduction, a
substantial reduction in the number of GER hospitalizations (30%)
and deaths (47%) was observed, compared to the baseline pre-
vaccination period. This decline was most pronounced in the
Panama region where vaccine coverage was the highest, suggest-
ing the likely impact of rotavirus vaccination. The number of
children receiving the ﬁrst dose of the rotavirus vaccine was more
than the number receiving both doses in all regions in the study.
Vaccine coverage for two doses during the ﬁrst year following the
introduction of the rotavirus vaccine in children aged <1 year
(2006) was only 30%. Nevertheless, this coverage increased to 62%Figure 2. Number of gastroenteritis-related deaths among children aged <5 years pre- an
CGR in Panama; population data provided by the Directorate of Statistics based on the p
Program on Immunization (EPI) of the Ministry of Health in Panama. Note: The mean in 2007 and 71% in 2008, leading to trends in reduction in the
number of GER hospitalizations and deaths.
A decrease in GER mortality rate by 45% (95% CI 40–51) was
observed in children <1 year of age and by 54% (95% CI 48–60) in
children 1–4 years of age during 2008, compared to the baseline
pre-vaccination period. These ﬁndings are consistent with data
from Mexico where a decline in the diarrhea-related mortality rate
of 41% for children aged <1 year and 29% for those children aged 1–
2 years was observed after the introduction of the human-
attenuated rotavirus vaccine.18A decreasing trend in GER mortality
rates was observed in 2007 in the Central and Panama regions, 1
year after the introduction of the rotavirus vaccine. However,
mortality rates did not show a signiﬁcant reduction in the West
and Northeast regions during 2007, probably because these
regions are inhabited by large migrant indigenous communities
with more limited access to medical care, poor sanitation, and low
vaccine coverage, making them more susceptible to infectious
diseases.
A phase III clinical trial of the human-attenuated rotavirus
vaccine in Latin America showed that all-cause GER hospitaliza-
tions were reduced by 39%,11,19 suggesting rotavirus vaccinationd post-rotavirus vaccination by region, Panama. (Source: Mortality data provided by
opulation census of the CGR; vaccination information obtained from the Expanded
baseline value is the mean number of GERD for the baseline period 2000–2005).
Figure 3. Trends over-time for gastroenteritis-related mortality rate by age group in Panama (2000–2008). aChi-square test for linear trend p < 0.05; bChi-square test for
linear trend p = 0.07. (Note: The gray line indicates when the human-attenuated rotavirus vaccine was introduced in 2006. Source: Mortality data provided by CGR in Panama;
population data provided by the Directorate of Statistics based on the population census of the CGR.).
Table 1
Gastroenteritis-related mortality rate (per 100 000) in Panama (2007 and 2008) compared with baseline period (2000–2005), by age group
Age group Baseline pre-vaccination period (2000–2005) 2007 2008
Mean mortality rate Mortality rate % Reduction (95% CI) Mortality rate % Reduction (95% CI)
<1 year 73 77 5 (7 to 4)a 40 45 (40 to 51)b
1–4 years 20.3 20.2 0.5 (0.7 to 0.8)a 9 54 (48 to 60)b
Overall 31.1 31.7 1.9 (1 to 3)a 15.5 50 (46 to 54)b
Source: Mortality data provided by CGR in Panama. Population data provided by the Directorate of Statistics based on the population census of the CGR.
a p > 0.05.
b p < 0.05.
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tis. In Panama, the number of GER hospitalizations in 2008
decreased by 28% in children aged <1 year and 31% in those aged
1–4 years, compared to the pre-vaccination period. A recent study
in Brazil has reported a reduction of approximately 48% in
hospitalizations among children <1 year of age.20 The reduction in
GER hospitalizations among children aged 1–4 years suggests a
possible herd protection effect.9,21
The annual report of the Ministry of Health of Panama did not
document any important changes with regards to interventions inFigure 4. Number of gastroenteritis-related hospitalizations by age group, pre- and pos
systematic review of ﬁve hospitals representing different settings in Panama (three urba
Miguel Arcangel; one suburban: Hospital Nicolas Solano; and 1 rural: Hospital de Changu
discharges for baseline period 2000–2005. The numbers within the bars are the relative r
compared with baseline.).sanitation, hygiene, or nutrition during 2007 and 2008 compared
to 2000–2005, thus it is likely that the decrease in GER outcomes is
an effect of vaccine introduction.22 Nonetheless, several caveats
must be considered when interpreting our ﬁndings. First, we had
limited access to data due to the lack of electronic records for
hospital discharges and also potential under-reporting of mortality
data in some regions. Second, this was an ecological study that was
limited to analyzing all-cause GER of presumed infectious origin
(not rotavirus-speciﬁc). Third, a potential cyclic pattern could be
suspected with regards to the number of GER hospitalizations andt-rotavirus vaccination in Panama. (Source: Hospital discharge data from database
n hospitals: Hospital del Nino, Hospital de Especialidades Pediatricas, Hospital San
inola). Note: The mean baseline value is the mean number of gastroenteritis hospital
eductions in the observed numbers of hospital discharges during 2008 and 2009, as
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and hospitalizations reported during 2008 have been the lowest
recorded in Panama. It is intended that the current study be
continued for a minimum of 3 years in order to capture cyclical
trends over time.
In conclusion, the ﬁndings of our study demonstrate reductions
in GER mortality and hospitalizations at only 2 years following the
introduction of the rotavirus vaccine into the routine immuniza-
tion schedule in Panama. A major impact was found in regions
where vaccination coverage was higher, suggesting that maximiz-
ing vaccine coverage could lead to further reductions in GER
mortality and hospitalizations. These data are the ﬁrst evidence
supporting the impact of vaccination among Panamanian children.
Continued monitoring and disease surveillance networks are
needed to further document the impact of rotavirus vaccination.
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